Hetlioz (tasimelteon) has been approved in the US for a few years to treat sleep disorders affecting people who are blind or ...

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

Judges in the First US Circuit Court of Appeals in Boston have rejected an effort to overturn last month's injunction on the ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on at a rate of 0.8 kg a month after the treatment stopped, which means that ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

Beyond the opportunities for start-ups, this change making direct primary care an eligible HSA expense represents a significant step in fighting chronic disease. This is because it allows the primary ...

OpenAI has announced ChatGPT Health, which promises to bring users' medical records and health and wellness apps like Apple ...